CN1969823A - Sustained release agent containing fluorouracil and synergist thereof - Google Patents
Sustained release agent containing fluorouracil and synergist thereof Download PDFInfo
- Publication number
- CN1969823A CN1969823A CNA2006102009415A CN200610200941A CN1969823A CN 1969823 A CN1969823 A CN 1969823A CN A2006102009415 A CNA2006102009415 A CN A2006102009415A CN 200610200941 A CN200610200941 A CN 200610200941A CN 1969823 A CN1969823 A CN 1969823A
- Authority
- CN
- China
- Prior art keywords
- release
- sustained
- injection
- combination
- paclitaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title claims abstract description 173
- 229960002949 fluorouracil Drugs 0.000 title claims abstract description 173
- 238000013268 sustained release Methods 0.000 title claims description 126
- 239000012730 sustained-release form Substances 0.000 title claims description 126
- 239000007924 injection Substances 0.000 claims abstract description 125
- 238000002347 injection Methods 0.000 claims abstract description 125
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims abstract description 83
- CXMXRPHRNRROMY-UHFFFAOYSA-N n-Decanedioic acid Natural products OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims abstract description 76
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 68
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 68
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 67
- 239000004005 microsphere Substances 0.000 claims abstract description 51
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims abstract description 51
- 229920001577 copolymer Polymers 0.000 claims abstract description 47
- 239000004626 polylactic acid Substances 0.000 claims abstract description 47
- 229960002066 vinorelbine Drugs 0.000 claims abstract description 46
- 230000001093 anti-cancer Effects 0.000 claims abstract description 44
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 40
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000375 suspending agent Substances 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 16
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920000954 Polyglycolide Polymers 0.000 claims abstract description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 14
- 229950004403 polifeprosan Drugs 0.000 claims abstract description 14
- 239000004633 polyglycolic acid Substances 0.000 claims abstract description 14
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 14
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 14
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims abstract description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 10
- 239000000600 sorbitol Substances 0.000 claims abstract description 10
- 235000010356 sorbitol Nutrition 0.000 claims abstract description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 9
- 229930195725 Mannitol Natural products 0.000 claims abstract description 9
- 239000000594 mannitol Substances 0.000 claims abstract description 9
- 235000010355 mannitol Nutrition 0.000 claims abstract description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 3
- 239000007943 implant Substances 0.000 claims description 50
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 47
- 229940127093 camptothecin Drugs 0.000 claims description 47
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 47
- 239000002904 solvent Substances 0.000 claims description 38
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 20
- 210000003491 skin Anatomy 0.000 claims description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- YADZBEISHVCBSJ-UHFFFAOYSA-N [I].OCC(O)CO Chemical compound [I].OCC(O)CO YADZBEISHVCBSJ-UHFFFAOYSA-N 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 229940008099 dimethicone Drugs 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 3
- 210000003238 esophagus Anatomy 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000003739 neck Anatomy 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 210000001989 nasopharynx Anatomy 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 70
- 238000000034 method Methods 0.000 abstract description 51
- 230000000694 effects Effects 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 21
- 239000000725 suspension Substances 0.000 abstract description 18
- 239000003795 chemical substances by application Substances 0.000 abstract description 13
- 239000005038 ethylene vinyl acetate Substances 0.000 abstract description 10
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- 230000005855 radiation Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 2
- 239000012747 synergistic agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 36
- 239000002504 physiological saline solution Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 210000004881 tumor cell Anatomy 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 20
- 229920000642 polymer Polymers 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 18
- 238000001694 spray drying Methods 0.000 description 16
- 238000002156 mixing Methods 0.000 description 14
- 230000004614 tumor growth Effects 0.000 description 14
- GDFUWFOCYZZGQU-UHFFFAOYSA-N 4-propoxybenzoic acid Chemical compound CCCOC1=CC=C(C(O)=O)C=C1 GDFUWFOCYZZGQU-UHFFFAOYSA-N 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 229940041181 antineoplastic drug Drugs 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 9
- ATZHGRNFEFVDDJ-UHFFFAOYSA-N 4-propylbenzoic acid Chemical compound CCCC1=CC=C(C(O)=O)C=C1 ATZHGRNFEFVDDJ-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000002601 intratumoral effect Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 229920005578 aromatic polyanhydride Polymers 0.000 description 6
- 238000007334 copolymerization reaction Methods 0.000 description 6
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 6
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 6
- 239000000693 micelle Substances 0.000 description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 but not limited to Chemical class 0.000 description 5
- 239000003405 delayed action preparation Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229920002101 Chitin Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- MJRDZKSKNYIAHZ-WLHGVMLRSA-N (e)-but-2-enedioic acid;decanedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)CCCCCCCCC(O)=O MJRDZKSKNYIAHZ-WLHGVMLRSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 229920005576 aliphatic polyanhydride Polymers 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229920001273 Polyhydroxy acid Polymers 0.000 description 2
- 229940124532 absorption promoter Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- LPRCVLBATUMNBP-UHFFFAOYSA-N decanedioic acid;propane Chemical compound CCC.OC(=O)CCCCCCCCC(O)=O LPRCVLBATUMNBP-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- ZJVATSUMFCZSKA-QZOPMXJLSA-N (z)-docos-13-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O ZJVATSUMFCZSKA-QZOPMXJLSA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Disclosed is an anticancer slow release injection containing fluorouracil and synergistic agents, which comprises slow release micro-balloons and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The suspending agent is selected from sodium carboxymethylcellulose, mannitol, sorbitol, Tween-80 or their combination. The anticancer active constituents are the combination of 5-FU and Paclitaxel, camptothecine and Vinorelbine. The slow release auxiliary materials are selected from polylactic acid, ethylene-vinylacetate copolymer, Polifeprosan, FAD, sebacic acid copolymer, polyglycolic acid and glycolic acid copolymer or their combination. The viscosity of the injection 50-1000cp (at 20-30 deg C). The slow release microspheres can also be prepared into slow release implanting agent. When in-tumor or around-tumor injected or placed, the slow release agent can not only lower down the whole body toxicity reaction of the anti-cancer medicament, but also can selectively increase the tumor local medicinal concentration, and improve the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation.
Description
(I) technical field
The invention relates to a sustained release preparation containing fluorouracil (5-FU) and a synergist thereof and a preparation method thereof, belonging to the technical field of medicines. The sustained release agent is mainly sustained release injection and sustained release implant.
(II) background of the invention
As a common chemotherapeutic drug, 5-fluorouracil (5-FU) is widely applied to the treatment of various malignant tumors and has obvious effect. However, its unexpected neurotoxicity greatly limits the use of this drug. Blood vessels, connective tissues, matrix proteins, fibrin and collagen in tumor stroma not only provide a scaffold and essential nutrients for the growth of tumor cells, but also influence the penetration and diffusion of chemotherapeutic drugs around tumors and in tumor tissues (see Niti et al, "influence of extracellular stroma conditions on drug transport in solid tumors" ("Cancer research 60: 2497 and 503 (2000)) (Netti PA, Cancer Res.2000, 60 (9): 2497503)). Due to the fact that solid tumors are over-swollen and hyperplastic, and the interstitial pressure, the tissue elastic pressure, the fluid pressure and the interstitial viscosity are higher than those of the surrounding normal tissues, the effective drug concentration is difficult to form locally in the tumor in conventional chemotherapy, see Kongqing et al, "cisplatin and systemic carmustine can be placed in the tumor to treat the brain tumor of rats" [ J. Otsugaku et al, J. Surginocol.1998 Oct. (69 (2): 7682) ], and the simple increase of the administration dose is limited by the systemic reaction. The local application of the medicine may solve the problem of the concentration of the medicine to some extent (Chinese patent), however, the operation operations such as medicine implantation and the like are complex and traumatic, and can cause or accelerate the diffusion and metastasis of tumors besides easily causing various complications such as bleeding, infection, immunity reduction and the like. In addition, the preparation itself before and after the operation and the high cost often affect the effective implementation.
In addition, DNA repair function in many tumor cells is significantly increased following chemotherapy. The latter often leads to an increased tolerance of the tumor cells to anticancer drugs, with consequent therapeutic failure.
In addition, low dose anti-cancer drug therapy not only increases drug tolerance but also promotes invasive growth of cancer cells (see beam et al, "increasing drug tolerance and in vitro infiltration capacity of human lung cancer cells with altered gene expression after anti-cancer drug pulse screening" [ J.Immunol.Cancer, 111, et al, pp.484-93 (2004) ] (Liang Y, et al, Int J cancer.2004; 111 (4): 484-93)).
Therefore, preparations and methods that facilitate the maintenance of high drug concentrations locally in tumors and increase the sensitivity of tumor cells to drugs have become an important subject of research.
Disclosure of the invention
5-fluorouracil is a commonly used anticancer drug and has been widely used for treating various tumors, such as colorectal cancer and the like. However, during the application process, the obvious systemic toxicity greatly limits the application of the medicine.
In order to effectively increase the local drug concentration of tumor and reduce the drug concentration of drug in the circulatory system, a drug sustained-release system containing 5-fluorouracil has been studied, which comprises sustained-release microspheres (capsules) (see (Chinese patent No. ZL 00809160.9; application No. 91109723.6), Ciftci K, etc. 'research on treating solid tumor and drug release using fluorouracil-containing polylactic acid microspheres' drug development technology (Pharm Dev Technol.)2 (2): 151-60, 1997), sustained-release implant (see (Chinese patent No. ZL 96115937.5; ZL97107076.8), etc. However, the solid sustained-release implant (Chinese patent No. ZL 96115937.5; ZL97107076.8) and the existing sustained-release microspheres for treating brain tumor (ZL00809160.9) or the U.S. Pat. No. 5,651,986 have the problems of difficult operation, poor curative effect, more complications and the like. In addition, many solid tumors are poorly sensitive to anticancer drugs, including 5-fluorouracil, and are susceptible to development of resistance during treatment. The present invention has found that the combination of 5-FU with the drug mentioned in the present invention enhances the anticancer effect (hereinafter, the drug capable of enhancing the anticancer effect of 5-FU is referred to as 5-FU potentiator).
In addition, the anti-cancer drug sustained-release injection prepared by packaging the combination of 5-FU and the synergist thereof in a specific sustained-release auxiliary material and matching with a special solvent can greatly improve the local drug concentration of tumors, reduce the drug concentration of the drugs in the circulatory system, reduce the toxicity of the drugs to normal tissues, greatly facilitate the drug injection, reduce the complications of surgical operation and reduce the cost of patients. The 5-FU synergist can inhibit tumor growth and increase the sensitivity of tumor cells to anticancer drugs.
The present invention has found that not all excipients are effective in releasing 5-FU. The medicinal auxiliary materials are more than hundreds of medicinal auxiliary materials with slow release function, in particular the medicinal auxiliary materials which can slowly release the 5-FU selected by the invention in human bodies or animal bodies within a certain time can be obtained through a large number of creative experiments, and the selection of the combination of the specific slow release auxiliary materials and the medicine which can be slowly released can be determined through a large number of creative labor. The related data, particularly the data of the release characteristics in animals, can be obtained through a large number of creative experiments in vivo and in vitro, can not be determined through limited experiments, and is non-obvious.
The sustained release of the local drug can ensure the lasting and stable drug concentration in the local application range, obviously reduce the drug concentration of the whole body and reduce the toxic and side effects.
Aiming at the defects of the prior art, the invention provides a sustained release preparation containing 5-FU and a synergist thereof. The sustained release preparation comprises an anticancer active ingredient and a medicinal sustained release adjuvant. Mainly comprises a slow release injection and a slow release implant
Aiming at the defects of the prior art, the invention provides a novel sustained-release injection containing fluorouracil and 5-fluorouracil synergist.
One form of the invention is a sustained-release injection, which consists of sustained-release microspheres and a solvent. Specifically, the anticancer sustained-release injection consists of the following components:
(A) a sustained release microsphere comprising:
0.5-60% of anticancer active ingredient
Sustained release auxiliary materials 40-99%
0.0 to 30 percent of suspending agent
The above are weight percentages
And
(B) the solvent is common solvent or special solvent containing suspending agent.
Wherein,
the anticancer effective component is 5-FU and 5-FU synergist, and the 5-FU synergist is selected from taxol, camptothecin, and vinorelbine; the slow release auxiliary material comprises one or the combination of the following components: the polylactic acid-based coating comprises one or a combination of racemic polylactic acid, racemic polylactic acid/glycolic acid copolymer, monomethyl polyethylene glycol/polylactic acid copolymer, polyethylene glycol/polylactic acid copolymer, carboxyl-terminated polylactic acid/glycolic acid copolymer, polifeprosan, di-fatty acid and sebacic acid copolymer, poly (erucic acid dimer-sebacic acid), poly (fumaric acid-sebacic acid), ethylene vinyl acetate copolymer, polylactic acid, polyglycolic acid and glycolic acid copolymer, xylitol, oligosaccharide, chondroitin, chitin, hyaluronic acid, collagen, gelatin and albumin glue.
Among the various polymers, preferred are polylactic acid, sebacic acid, and a mixture or copolymer of polylactic acid and sebacic acid, and the mixture or copolymer can be selected from, but not limited to, PLA, PLGA, a mixture of glycolic acid and hydroxycarboxylic acid, and a mixture or copolymer of sebacic acid and an aromatic polyanhydride or an aliphatic polyanhydride. The blending ratio of glycolic acid and hydroxycarboxylic acid is 10/90-90/10 (by weight), preferably 25/75-75/25 (by weight). The method of blending is arbitrary. The contents of glycolic acid and hydroxycarboxylic acid in copolymerization are 10-90 wt% and 90-10 wt%, respectively. Representative of the aromatic polyanhydrides are polifeprosan [ poly (1, 3 di (P-carboxyphenoxy) propane-sebacic acid) (P (CPP-SA)), di-fatty acid sebacic acid copolymer (PFAD-SA) ], poly (erucic acid dimer sebacic acid) [ P (EAD-SA) ], and poly (fumaric acid sebacic acid) [ P (FA-SA) ], and the like. The content of p-carboxyphenoxy propane (p-CPP) and sebacic acid in copolymerization is 10-60 wt% and 20-90 wt%, respectively, and the blending weight ratio is 10-40: 50-90, preferably 15-30: 65-85.
The molecular weight peak of polylactic acid may be, but is not limited to, 5000-100,000, but is preferably 20,000-60,000, and most preferably 5,000-30,000; the molecular weight of polyglycolic acid may be, but is not limited to, 5000-; the polyhydroxy acids can be selected singly or in multiple ways. When selected alone, polylactic acid (PLA) or a copolymer of hydroxycarboxylic acid and glycolic acid (PLGA) is preferred, and the molecular weight of the copolymer may be, but is not limited to, 5000-100,000, but is preferably 20,000-60,000, and is most preferably 30,000-50,000; when more than one choice is selected, the polymer or the composite polymer or copolymer of different polymers is preferred, and the composite polymer or copolymer of polylactic acid or sebacic acid with different molecular weight is most preferred, such as, but not limited to, polylactic acid with molecular weight of 1000 to 30000 mixed with polylactic acid with molecular weight of 20000 to 50000, polylactic acid with molecular weight of 10000 to 30000 mixed with PLGA with molecular weight of 30000 to 80000, polylactic acid with molecular weight of 20000 to 30000 mixed with sebacic acid, PLGA with molecular weight of 30000 to 80000 mixed with sebacic acid. The polylactic acid used is preferably L-polylactic acid (L-PLA). The viscosity range IV (dl/g) of the L-polylactic acid (L-PLA) is 0.2-0.8, the glass transition temperature range is 55-65 ℃, and the melting point is 175-185 ℃.
In addition to the above sustained-release excipients, other substances can be selected and used as described in detail in U.S. Pat. Nos. 4757128, 4857311, 4888176 and 4789724 and "pharmaceutical excipients" in general (p. 123, published by Sichuan scientific and technical Press 1993, compiled by Roming and Gaoyun). In addition, Chinese patent (application No. 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S. patent No. 5,651,986) also list some pharmaceutical excipients, including fillers, solubilizers, absorption promoters, film-forming agents, gelling agents, pore-forming agents, excipients or retarders
In order to adjust the drug release rate or change other characteristics of the present invention, the monomer component or molecular weight of the polymer can be changed, and the composition and ratio of the pharmaceutical excipients can be added or adjusted, and water-soluble low molecular compounds such as, but not limited to, various sugars or salts can be added. Wherein the sugar can be, but is not limited to, xylitol, oligosaccharide, (chondroitin sulfate), chitin, etc., and the salt can be, but is not limited to, potassium salt, sodium salt, etc.; other pharmaceutical adjuvants such as, but not limited to, fillers, solubilizers, absorption enhancers, film-forming agents, gelling agents, pore-forming agents, excipients, or retarders may also be added.
The weight percentage of the synergist (paclitaxel, camptothecin and vinorelbine) in the sustained release agent is 0.1-60%, preferably 1-50%, and most preferably 5-30%.
The anticancer active ingredient is the combination of 5-FU and a synergist thereof. When the anticancer drug in the drug sustained-release microspheres is only 5-FU synergist, the anticancer sustained-release injection is mainly used for increasing the effect of 5-FU applied by other ways or the synergism of radiotherapy or other therapies. When used for increasing the action effect of 5-FU applied by other routes, the 5-FU can be administered by artery, vein or local injection and placement.
The weight percentage of the anticancer active ingredients in the sustained-release microspheres is 0.5-60%, preferably 2-40%, and most preferably 5-30%. The weight ratio of the 5-FU to the 5-FU synergist is 1-9: 1 to 1: 1-9. Preferably 1-2: 1.
The anticancer active ingredients in the anticancer sustained-release microspheres of the invention preferably have the following weight percentages:
5-30% of 5-FU in combination with 5-30% of paclitaxel, camptothecin or vinorelbine.
The weight percentage of the anticancer active ingredients in the anticancer sustained-release microspheres is most preferably as follows:
(a) 5-30% of 5-FU and 5-30% of paclitaxel;
(b) 5-30% of 5-FU and 5-30% of camptothecin;
(c) 5-30% of 5-FU and 5-30% of vinorelbine.
The sustained release excipient is preferably one or a combination of polylactic acid (PLA), polyglycolic acid and glycolic acid copolymer (PLGA), ethylene vinyl acetate copolymer (EVAc), FAD: SA copolymer and polifeprosan.
When polylactic acid (PLA), polyglycolic acid (PGA), a mixture of polylactic acid (PLA) and polyglycolic acid, and a copolymer of glycolic acid and hydroxycarboxylic acid (PLGA) are selected, the contents of PLA and PLGA are 0.1-99.9% and 99.9-0.1% by weight, respectively. The molecular weight peak of polylactic acid can be, but is not limited to, 5000-; the molecular weight of polyglycolic acid may be, but is not limited to, 5000-; the polyhydroxy acids can be selected singly or in multiple ways. When selected individually, polylactic acid (PLA) or a copolymer of hydroxycarboxylic acid and glycolic acid (PLGA) is preferred, and the molecular weight of the copolymer may be, but is not limited to, 5000-; when more than one choice is selected, the polymer or the composite polymer or copolymer of different polymers is preferred, and the composite polymer or copolymer of polylactic acid or sebacic acid with different molecular weight is most preferred, such as, but not limited to, polylactic acid with molecular weight of 1000 to 30000 mixed with polylactic acid with molecular weight of 20000 to 50000, polylactic acid with molecular weight of 10000 to 30000 mixed with PLGA with molecular weight of 30000 to 80000, polylactic acid with molecular weight of 20000 to 30000 mixed with sebacic acid, PLGA with molecular weight of 30000 to 80000 mixed with sebacic acid.
Among the various polymers, preferred are polylactic acid, sebacic acid, and a mixture or copolymer of polylactic acid and sebacic acid, and the mixture or copolymer can be selected from, but not limited to, PLA, PLGA, a mixture of glycolic acid and hydroxycarboxylic acid, and a mixture or copolymer of sebacic acid and an aromatic polyanhydride or an aliphatic polyanhydride. The blending ratio of glycolic acid and hydroxycarboxylic acid is 10/90-90/10 (by weight), preferably 25/75-75/25 (by weight). The method of blending is arbitrary. The contents of glycolic acid and hydroxycarboxylic acid in copolymerization are 10-90 wt% and 90-10 wt%, respectively. Representative of the aromatic polyanhydrides are polifeprosan [ poly (1, 3-di (P-carboxyphenoxy) propane sebacic acid) (P (CPP-SA)), di-fatty acid sebacic acid copolymer (PFAD-SA) ], poly (erucic acid dimer-sebacic acid) [ P (EAD-SA) ], and poly (fumaric acid-sebacic acid) [ P (FA-SA) ], and the like. The content of p-carboxyphenoxy propane (p-CPP) and sebacic acid in copolymerization is 10-60 wt% and 20-90 wt%, respectively, and the blending weight ratio is 10-40: 50-90, preferably 15-30: 65-85.
In addition to the above-mentioned adjuvants, other substances may be selected and used as described in detail in U.S. Pat. Nos. 4757128, 4857311, 4888176, 4789724 and the "pharmaceutical adjuvants Pan" (published by Sichuan scientific and technical Press 1993, published by Luoming and high-tech Master), and further, some pharmaceutical adjuvants including fillers, solubilizers, absorption promoters, film-forming agents, gelling agents, pore-forming agents, excipients or retarders are listed in the Chinese patent No. 96115937.5, 91109723.6, 9710703.3, 01803562.0 and the U.S. patent No. 5,651,986).
In order to adjust the drug release rate or change other characteristics of the present invention, the monomer component or molecular weight of the polymer can be changed, and the composition and ratio of the pharmaceutical excipients can be added or adjusted, and water-soluble low molecular compounds such as, but not limited to, various sugars or salts can be added. The sugar can be, but is not limited to, xylitol, oligosaccharide, (chondroitin sulfate), chitin, etc., and the salt can be, but is not limited to, potassium salt, sodium salt, etc.
In the slow release injection, the drug slow release system can be prepared into microspheres, submicron spheres, micro emulsion, nanospheres, granules or spherical pellets, and then the injection is prepared after the drug slow release system is mixed with an injection solvent. The suspension type sustained-release injection is preferably selected from various sustained-release injections, the suspension type sustained-release injection is a preparation obtained by suspending a drug sustained-release system containing an anticancer component in injection, the used auxiliary materials are one or the combination of the sustained-release auxiliary materials, and the used solvent is a common solvent or a special solvent containing a suspending agent. Common solvents are, but not limited to, distilled water, water for injection, physiological saline, absolute ethanol or buffers formulated with various salts. The purpose of the suspending agent is to effectively suspend the microspheres containing the drug, thereby facilitating injection.
The suspending agent is selected from one or more of sodium carboxymethylcellulose, (iodine) glycerol, dimethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, Tween 20, Tween 40 and Tween 80.
The content of the suspending agent in the common solvent is determined by the characteristics of the suspending agent, and can be 0.1-30% according to the specific situation. Preferably, the suspending agent consists of:
(a) 0.5-5% of sodium carboxymethylcellulose and 0.1-0.5% of Tween 80; or
(b) 5-20% of mannitol and 0.1-0.5% of Tween 80; or
(c)0.5 to 5 percent of sodium carboxymethylcellulose, 5 to 20 percent of sorbitol and 0.1 to 0.5 percent of Tween 80.
The preparation of the solvent depends on the kind of the solvent, and common solvents are commercially available or self-made, such as distilled water, water for injection, physiological saline, absolute ethanol or buffers prepared from various salts, but the preparation must strictly follow the relevant standards. The special solvent should consider the type and composition of suspending agent, the composition and properties of the drug suspended in the solvent, the sustained release microsphere (or microcapsule) and the required amount thereof, and the preparation method of the injection, for example, sodium carboxymethylcellulose (1.5%) + mannitol and/or sorbitol (15%) and/or tween 80 (0.1%) are dissolved in physiological saline to obtain the corresponding solvent, the viscosity is 10-650 cp (at 20-30 ℃).
The invention discovers that the key factor influencing the suspension and/or injection of the medicament and/or the sustained-release microspheres is the viscosity of the solvent, and the higher the viscosity is, the better the suspension effect is and the stronger the injectability is. This unexpected finding constitutes one of the main exponential features of the present invention. The viscosity of the solvent depends on the viscosity of the suspending agent, and the viscosity of the suspending agent is 100cp-3000cp (at 20-30 ℃), preferably 1000cp-3000cp (at 20-30 ℃), and most preferably 1500cp-3000cp (at 20-30 ℃). The viscosity of the solvent prepared according to the condition is 10cp-650cp (at 20-30 ℃), preferably 20cp-650cp (at 20-30 ℃), and most preferably 60cp-650cp (at 20-30 ℃).
The preparation of injection has several methods, one is that the slow release particles (A) whose suspending agent is '0' are directly mixed in special solvent to obtain correspondent slow release particle injection; the other is that the slow release particles (A) of which the suspending agent is not 0 are mixed in a special solvent or a common solvent to obtain the corresponding slow release particle injection; and the other one is that the slow release particles (A) are mixed in common dissolvent, then suspending agent is added and mixed evenly, and the corresponding slow release particle injection is obtained. Besides, the sustained-release particles (A) can be mixed in a special solvent to prepare a corresponding suspension, then the water in the suspension is removed by methods such as vacuum drying, and the like, and then the suspension is suspended by the special solvent or a common solvent to obtain a corresponding sustained-release particle injection. The above methods are merely illustrative and not restrictive of the invention. It is noted that the concentration of the suspended drug or the sustained release microspheres (or microcapsules) in the injection may be, but is not limited to, 10-400mg/ml, preferably 30-300mg/ml, and most preferably 50-200mg/ml, depending on the particular needs. The viscosity of the injection is 50-1000 cp (at 20-30 deg C), preferably 100-1000 cp (at 20-30 deg C), and most preferably 200-650 cp (at 20-30 deg C). This viscosity is suitable for 18-22 gauge needles and specially made needles with larger (to 3 mm) inside diameters.
The method of preparation of the sustained release injection is arbitrary and can be prepared by several methods: such as, but not limited to, mixing, melting, dissolving, spray drying to prepare microspheres, dissolving in combination with freezing (drying) and pulverizing to form fine powders, liposome-encapsulating, and emulsifying. Among them, a dissolving method (i.e., solvent evaporation method), a drying method, a spray drying method and an emulsification method are preferable. The microspheres can be used for preparing the various sustained-release injections, and the method is arbitrary. The microspheres used may have a particle size in the range of 5-400um, preferably 10-300um, most preferably 20-200 um.
The microspheres can also be used for preparing other sustained-release injections, such as gel injections and block copolymer micelle injections. The block copolymer micelle is formed by a hydrophobic-hydrophilic block copolymer in an aqueous solution and has a spherical core-shell structure, wherein the hydrophobic block forms a core, and the hydrophilic block forms a shell. The drug-loaded micelle is injected into the body to achieve the purpose of controlling the release of the drug or targeting therapy. The drug carrier is any one of the above or the combination thereof. Of these, polyethylene glycol (PEG) having a molecular weight of 1000-15000 is preferable as the hydrophilic block of the micelle copolymer, and biodegradable polymers such as PLA, polylactide, polycaprolactone and copolymers thereof (molecular weight 1500-25000) are preferable as the hydrophobic block of the micelle copolymer. The block copolymer micelles may have a particle size in the range of 10 to 300um, preferably 20 to 200 um. The gel injection is prepared by dissolving biodegradable polymer (such as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer) in certain amphiphilic solvent, adding the medicine, mixing (or suspending) with the solvent to form gel with good fluidity, and can be injected around tumor or in tumor. Once injected, the amphiphilic solvent diffuses into the body fluid quickly, and the water in the body fluid permeates into the gel, so that the polymer is solidified and the drug is released slowly.
The sustained-release microspheres can also be used for preparing sustained-release implants, the used pharmaceutical excipients can be any one or more of the above pharmaceutical excipients, but water-soluble high molecular polymers are taken as the main choice, and in various high molecular polymers, polylactic acid, sebacic acid, a mixture or copolymer of high molecular polymers containing polylactic acid or sebacic acid are taken as the first choice, and the mixture and copolymer can be selected from, but are not limited to, PLA, PLGA, a mixture of PLA and PLGA, and a mixture or copolymer of sebacic acid and aromatic polyanhydride or aliphatic polyanhydride. The blending ratio of polylactic acid (PLA) to polyglycolic acid is 10/90 to 90/10 (by weight), preferably 25/75 to 75/25 (by weight). The method of blending is arbitrary. The contents of glycolic acid and lactic acid in copolymerization are respectively 10-90% and 90-10% by weight. The aromatic polyanhydride is represented by p-carboxyphenylpropane (p-CPP), the content of the p-carboxyphenylpropane (p-CPP) and sebacic acid in copolymerization is respectively 10-60% and 20-90% by weight, and the blending weight ratio is 10-40: 50-90, preferably 15-30: 65-85.
The other form of the anticancer drug sustained release preparation of the invention is that the anticancer drug sustained release preparation is a sustained release implant. The effective components of the anticancer implant can be uniformly packaged in the whole pharmaceutic adjuvant, and also can be packaged in the center of a carrier support or on the surface of the carrier support; the active principle can be released by direct diffusion and/or by degradation via polymers.
The slow release implant is characterized in that the slow release auxiliary material contains any one or more of the other auxiliary materials besides the high molecular polymer. The added pharmaceutic adjuvants are collectively called as additives. The additives can be classified into fillers, pore-forming agents, excipients, dispersants, isotonic agents, preservatives, retarding agents, solubilizers, absorption enhancers, film-forming agents, gelling agents, etc. according to their functions.
The main components of the sustained-release implant can be prepared into various dosage forms. Such as, but not limited to, capsules, sustained release formulations, implants, sustained release implants, and the like; in various shapes such as, but not limited to, granules, pills, tablets, powders, granules, spheres, chunks, needles, rods, columns, and films. Among various dosage forms, slow release implants in vivo are preferred.
The optimal dosage form of the sustained-release implant is a biocompatible, degradable and absorbable sustained-release implant, and can be prepared into various shapes and various dosage forms according to different clinical requirements. The packaging method and procedure for its main ingredients are described in detail in US patent (US5651986) and include several methods for preparing sustained release formulations: such as, but not limited to, (i) mixing a carrier support powder with a drug and then compressing into an implant, a so-called mixing process; (ii) melting the carrier support, mixing with the drug to be packaged, and then cooling the solid, the so-called melt process; (iii) dissolving the carrier support in a solvent, dissolving or dispersing the drug to be packaged in a polymer solution, and then evaporating the solvent and drying, the so-called dissolution method; (iv) spray drying; and (v) freeze-drying method.
The weight percentage of the anticancer active ingredients in the sustained-release implant is as follows, 5-30% of 5-FU and 5-30% of the combination of taxol, camptothecin and vinorelbine.
The weight percentage of the anticancer active ingredients in the sustained-release implant is most preferably as follows:
(a) 5-30% of 5-FU and 5-30% of paclitaxel;
(b) 5-30% of 5-FU and 5-30% of camptothecin;
(c) 5-30% of 5-FU and 5-30% of vinorelbine.
The sustained release excipient is preferably one or a combination of polylactic acid (PLA), polyglycolic acid and glycolic acid copolymer (PLGA), ethylene vinyl acetate copolymer (EVAc), FAD: SA copolymer and polifeprosan.
The invention can be used for preparing pharmaceutical preparations for treating various tumors of human and animals, and is mainly a sustained-release injection or a sustained-release implant. The prepared tumors comprise various solid tumors. Including primary or metastatic cancers originating in the brain and central nervous system, and various solid tumors originating extracranially, such as primary or metastatic cancers of the kidney, liver, gallbladder, head and neck, oral cavity, thyroid, skin, mucosa, glands, blood vessels, bone tissue, lymph nodes, lung, esophagus, stomach, breast, pancreas, eye, nasopharynx, uterus, ovary, endometrium, cervix, prostate, bladder, colon, rectum, or sarcoma or carcinosarcoma, with brain, kidney, head and neck, thyroid, lung, esophagus, stomach, breast, pancreas, cervix, ovary, prostate, bladder, colorectal, or metastatic cancers being preferred.
The route of administration depends on a variety of factors, and in order to achieve effective concentrations at the site of the primary or metastatic tumor, the drug may be administered by a variety of routes, such as subcutaneous, intraluminal (e.g., intraperitoneal, thoracic, and intravertebral), intratumoral, peritumoral injection or placement, selective arterial injection, intralymph node, and intramedulary injection. Selective arterial injection, intracavitary, intratumoral, peritumoral injection or placement is preferred. Can be injected or placed in or around tumor during or before operation; can be applied simultaneously with or separately before and after radiation and systemic chemotherapy, but the slow release implant is preferably injected or placed in or around tumor.
The sustained-release injection or the sustained-release implant prepared by the invention can also be added with other medicinal components, such as, but not limited to, antibiotics, analgesic drugs, anticoagulant drugs, hemostatic drugs and the like.
The technical process of the invention is further described by the following tests and examples:
test 1 comparison of local drug concentrations after different modes of application of 5-FU
The white rat is used as a testObject, 2X 105Individual prostate tumor cells were injected subcutaneously into the quaternary costal region and divided into the following 8 groups after the tumors had grown to 1 cm diameter (see table 1). The dose of each group was 5 mg/kg. The content (%) of the drug in the tumor was measured at different times.
TABLE 1
Test set (n) | Mode of administration | The amount of drug in the tumor on day one | The content of the drug in the tumor on the third day | The drug content in the tumor on day 7 |
1(3) | Tail vein injection common injection | 0.60 | 0.32 | 0.12 |
2(3) | Common injection for intraperitoneal injection | 0.56 | 0.3 | 0.08 |
3(3) | General injection for injection around tumor | 2.6 | 1.2 | 0.3 |
4(3) | Tumor injection slow-release injection | 10 | 18 | 20 |
5(3) | Slow release implant placed around tumor | 18 | 30 | 32 |
6(3) | General injection for intratumoral injection | 4 | 2 | 1 |
7(3) | Sustained-release injection for intratumoral injection | 92 | 80 | 60 |
8(3) | Sustained-release implant placed in tumor | 94 | 92 | 86 |
The results show that the local drug concentration difference of the 5-FU applied in different modes is obvious, the local administration can obviously improve and effectively maintain the effective drug concentration of the tumor part, and the effect of placing the sustained-release implant in the tumor and injecting the sustained-release injection in the tumor is the best. However, the intratumoral injection of the sustained-release injection is most convenient and easy to operate. This finding constitutes an important feature of the present invention. This is further confirmed by the following relevant tumor inhibition test.
Experiment 2 comparison of in vivo tumor inhibition after application of 5-FU in different ways
Using white rat as test object, 2X 105Individual prostate tumor cells were injected subcutaneously into the quaternary costal region and divided into the following 9 groups after the tumors had grown to a diameter of 0.5 cm (see table 2). The dose of each group was 5 mg/kg. The volume of the tumor was measured on the 20 th day after treatment, and the therapeutic effect was compared.
TABLE 2
Test set (n) | Mode of administration | Tumor volume (cm)3) | P value |
1(6) | - | 70 | |
2(6) | Tail vein injection common injection | 68 | 0.05 |
3(6) | Common injection for intraperitoneal injection | 64 | 0.05 |
4(6) | General injection for injection around tumor | 56 | 0.04 |
5(6) | Tumor injection slow-release injection | 34 | <0.01 |
6(6) | Slow release implant placed around tumor | 22 | <0.01 |
7(6) | General injection for intratumoral injection | 52 | 0.03 |
8(6) | Sustained-release injection for intratumoral injection | 20 | <0.001 |
9(6) | Sustained-release implant placed in tumor | 18 | <0.001 |
The results show that the tumor inhibition effect difference of the 5-FU applied in different modes is obvious, the effective drug concentration of the tumor part can be obviously improved and effectively maintained by local administration, and the effect of placing the sustained-release implant in the tumor and injecting the sustained-release injection in the tumor is the best. However, the intratumoral injection of the sustained-release injection is most convenient and easy to operate. Not only has good curative effect, but also has little toxic and side effect.
Experiment 3, in vivo tumor inhibiting effect of synergist containing 5-FU and 5-FU (sustained release injection)
Using rat (Fisher344) as test object, 2 × 105Individual pancreatic tumor cells were injected subcutaneously into the quaternary costal region and were divided into the following 10 groups 14 days after tumor growth (see table 3). The first group was the control, and groups 2 to 10 were the treatment groups, and the drug was injected intratumorally. The dosage is shown in the table. Tumor volume was measured on day 20 after treatment and the treatment effect was compared (see table 3).
TABLE 3
Test set (n) | Is receiving treatment (mg/kg) | Tumor volume (cm)3) | P value |
1(6) | Control | 52±12 | |
2(6) | 5-FU(1) | 44±10.4 | <0.05 |
3(6) | 5-FU(2) | 34±8.0 | <0.01 |
4(6) | 5-FU(4) | 32±6.2 | <0.01 |
5(6) | 5-FU(8) | 24±6.0 | <0.01 |
6(6) | Paclitaxel (4) | 36±6.0 | <0.01 |
7(6) | 5-FU (1) + taxol | 32±6.2 | <0.001 |
8(6) | 5-FU (2) + taxol | 28±4.8 | <0.001 |
9(6) | 5-FU (4) + taxol | 20±3.6 | <0.001 |
10(6) | 5-FU (8) + taxol | 16±2.0 | <0.001 |
The results show that 5-FU and the used 5-FU synergist (taxol) have obvious inhibition effect on tumor growth when being used alone at the concentration, and can show obvious synergistic effect when being used together. Among them, the inhibitory effect of 5-FU on tumor growth is dose-dependent.
Tests on the antitumor Effect of 4, 5-FU and 5-FU potentiators (sustained-release injections)
The tumor cells include CNS-1, C6, 9L, gastric gland epithelial cancer (SA), bone tumor (BC), breast cancer (BA), lung cancer (LH), papillary thyroid adenocarcinoma (PAT), and liver cancer. 5-FU and 5-FU potentiator were added to each tumor cell cultured in vitro for 24 hours at a concentration of 10. mu.g/ml, and the total number of cells was counted after further culturing for 48 hours. The tumor cell growth inhibitory effect is shown in Table 4.
TABLE 4
Tumor cell | 5-FU | Camptothecin | Vinorelbine | Paclitaxel | 5-FU + camptothecin | 5-FU + vinorelbine | 5-FU + paclitaxel |
CNS | 58% | 52% | 64% | 42% | 90% | 84% | 90% |
C6 | 54% | 64% | 64% | 44% | 94% | 84% | 90% |
SA | 48% | 62% | 56% | 42% | 88% | 90% | 92% |
BC | 44% | 64% | 54% | 34% | 94% | 84% | 82% |
BA | 48% | 60% | 62% | 50% | 90% | 90% | 90% |
LH | 50% | 58% | 62% | 48% | 90% | 88% | 84% |
PAT | 58% | 52% | 52% | 34% | 94% | 86% | 92% |
The results show that the 5-FU and the 5-FU synergist (camptothecin, vinorelbine and taxol) have obvious inhibition effect on the growth of various tumor cells when being singly applied at the concentration, and can show obvious synergistic effect when being jointly applied.
Tests on the tumor-inhibiting action of 5, 5-FU and 5-FU synergist (sustained-release injection)
Using white rat as test object, 2X 105Individual liver tumor cells were injected subcutaneously into the quaternary costal region and divided into the following 8 groups 14 days after tumor growth (see table 5). The first group was the control, and groups 2 to 8 were the treatment groups, with the sustained release implant placed intratumorally. The dosages of 5-FU and synergist are respectively 5mg/kg and 2.5 mg/kg. Tumor volume was measured on day 20 after treatment and the effect was compared (see table 5).
TABLE 5
Test set (n) | Is treated by | Tumor volume (cm)3) | P value |
1(6) | Control | 50±10 | |
2(6) | Paclitaxel | 42±8.4 | <0.05 |
3(6) | 5-FU | 36±6.8 | <0.01 |
4(6) | Paclitaxel +5-FU | 30±6.4 | <0.001 |
5(6) | Camptothecin | 46±6.0 | <0.01 |
6(6) | Camptothecin +5-FU | 30±6.0 | <0.001 |
7(6) | Vinorelbine | 36±6.8 | <0.01 |
8(6) | Vinorelbine +5-FU | 22±4.6 | <0.001 |
The results show that the 5-FU and the 5-FU synergist (taxol, camptothecin and vinorelbine) have obvious inhibition effect on the growth of various tumor cells when being singly applied at the concentration, and can show obvious synergistic effect when being jointly applied.
Tests on the antitumor Effect of 6, 5-FU and 5-FU potentiators (sustained-release injections)
Using white rat as test object, 2X 105Individual prostate tumor cells were injected subcutaneously into the limbus, and after 14 days of tumor growth they were divided into negative controls (blank), single drug treatment groups (5-FU or 5-FU potentiator), and combination treatment groups (5-FU and 5-FU potentiator). The medicine is injected intratumorally. The dosages of 5-FU and synergist are shown in Table 6. The volume of the tumor was measured on day 30 after the treatment, and the therapeutic effect was compared using the tumor growth inhibition rate as an index (see Table 6).
TABLE 6
Test set (n) | Is receiving treatment (mg/kg) | Tumor inhibition ratio (%) | P value |
1(6) | Control | - | |
2(6) | 5-FU(4) | 50 | <0.05 |
3(6) | Paclitaxel (1) | 44 | <0.01 |
4(6) | Paclitaxel (2) | 48 | <0.01 |
5(6) | Paclitaxel (4) | 58 | <0.01 |
6(6) | Paclitaxel (8) | 62 | <0.01 |
7(6) | 5-FU + paclitaxel (1) | 72 | <0.001 |
8(6) | 5-FU + paclitaxel (2) | 80 | <0.001 |
9(6) | 5-FU + paclitaxel (4) | 88 | <0.001 |
10(6) | 5-FU + paclitaxel (8) | 92 | <0.001 |
The results show that the 5-FU and the 5-FU synergist (taxol) have obvious inhibition effect on the growth of tumor cells when being independently used at the concentration, and can show obvious synergistic effect when being used in combination.
Tests on the antitumor Effect of 7, 5-FU and 5-FU potentiators (sustained-release injections)
Using rat (Fisher344) as test object, 2 × 105Each breast tumor cell was injected subcutaneously into the costal region of the patient, and the tumor was divided into a negative control (blank), a single drug treatment group, and a combination treatment group 14 days after the tumor had grown. The medicine is injected intratumorally. The dosages of 5-FU and synergist are shown in Table 7. The volume of the tumor was measured on day 30 after the treatment, and the therapeutic effect was compared using the tumor growth inhibition rate as an index (see Table 7).
TABLE 7
Test set (n) | Is receiving treatment (mg/kg) | Tumor inhibition ratio (%) | P value |
1(6) | Control | - | |
2(6) | 5-FU(5) | 54 | <0.05 |
3(6) | Camptothecin (1) | 40 | <0.01 |
4(6) | Camptothecin (2) | 48 | <0.01 |
5(6) | Camptothecin (4) | 52 | <0.01 |
6(6) | Camptothecin (8) | 56 | <0.01 |
7(6) | 5-FU + camptothecin (1) | 68 | <0.001 |
8(6) | 5-FU + camptothecin (2) | 78 | <0.001 |
9(6) | 5-FU + camptothecin (4) | 84 | <0.001 |
10(6) | 5-FU + camptothecin (8) | 90 | <0.001 |
The results show that the 5-FU and the 5-FU synergist (camptothecin) have obvious inhibition effect on the growth of tumor cells when being used independently at the concentration, and can show obvious synergistic effect when being used together.
Tests on the antitumor Effect of 8, 5-FU and 5-FU synergists (sustained-release implants)
Using white rat as test object, 2X 105Each breast tumor cell was injected subcutaneously into the costal region of the patient, and the tumor was divided into a negative control (blank), a single drug treatment group, and a combination treatment group 14 days after the tumor had grown. The sustained release implant is placed intratumorally. Tumor volume was measured on day 20 after treatment, and the therapeutic effect was compared using tumor growth inhibition as an index (see table 8).
TABLE 8
Test set (n) | Is receiving treatment (mg/kg) | Tumor inhibition ratio (%) | P value |
1(6) | Control | - | |
2(6) | 5-FU(10) | 66 | <0.05 |
3(6) | Paclitaxel (2) | 38 | <0.05 |
4(6) | Paclitaxel (4) | 46 | <0.05 |
5(6) | Paclitaxel (8) | 54 | <0.05 |
6(6) | Paclitaxel (16) | 60 | <0.01 |
7(6) | 5-FU + paclitaxel (2) | 78 | <0.01 |
8(6) | 5-FU + paclitaxel (4) | 84 | <0.01 |
9(6) | 5-FU + paclitaxel (8) | 86 | <0.01 |
10(6) | 5-FU + paclitaxel (16) | 96 | <0.001 |
The results show that the 5-FU and the 5-FU synergist (taxol) have obvious inhibition effect on the growth of tumor cells when being independently used at the concentration, and can show obvious synergistic effect when being jointly used, and the synergistic effect is in a dose-effect relationship.
Tests 9, 5-FU and 5-FU potentiators (sustained-release implants) for tumor inhibition
The tumor-inhibiting effect of 5-FU and 5-FU potentiators (sustained-release implants) was measured as described in test 8, and the tumor growth inhibition rate thereof is shown in Table 9.
TABLE 9
Test set (n) | Is receiving treatment (mg/kg) | Tumor inhibition ratio (%) | P value |
1(6) | Control | - | |
2(6) | 5-FU(8) | 56 | <0.05 |
3(6) | Vinorelbine (2) | 32 | <0.05 |
4(6) | Vinorelbine (4) | 40 | <0.05 |
5(6) | Vinorelbine (8) | 52 | <0.05 |
6(6) | Vinorelbine (16) | 62 | <0.01 |
7(6) | 5-FU + vinorelbine (2) | 76 | <0.01 |
8(6) | 5-FU + vinorelbine (4) | 82 | <0.01 |
9(6) | 5-FU + vinorelbine (8) | 88 | <0.01 |
10(6) | 5-FU + vinorelbine (16) | 94 | <0.001 |
The results show that the 5-FU and the 5-FU synergist (vinorelbine) have obvious inhibition effect on the growth of various tumor cells when being used independently at the concentration, and can show obvious synergistic effect when being used in combination.
In conclusion, the 5-FU and various 5-FU synergists have obvious inhibition effect on the growth of various tumor cells when being used independently, and can show obvious synergistic effect when being used in combination. Therefore, the effective component of the invention is the combination of 5-FU and any 5-FU synergist. The medicine containing the above effective components can be made into sustained release microsphere, and further made into sustained release injection and implant, wherein suspension injection formed by combining with special solvent containing suspending agent is preferred.
The sustained-release injection or sustained-release implant can be further explained by the following embodiments. The above examples and the following examples are only for further illustration of the present invention and are not intended to limit the contents and uses thereof in any way.
(IV) detailed description of the preferred embodiments
Example 1.
80mg of polifeprosan (p-carboxyphenylpropane (p-CPP): Sebacic Acid (SA) is 20: 80) copolymer is respectively put into a container, then 100 ml of dichloromethane is added, 10mg of 5-FU and 10mg of paclitaxel are added after the mixture is dissolved and mixed evenly, and the microspheres for injection containing 10 percent of 5-FU and 10 percent of paclitaxel are prepared by a spray drying method after the mixture is shaken again evenly. Then suspending the microspheres in physiological saline containing 15 percent mannitol to prepare the corresponding suspension type sustained-release injection with the viscosity of 360-480 cp (at 25-30 ℃). The slow release injection has the release time of 10-15 days in-vitro physiological saline and the release time of about 20-30 days under the skin of a mouse.
Example 2.
80mg of polifeprosan (p-carboxyphenylpropane (p-CPP): Sebacic Acid (SA) 50: 50) copolymer is respectively put into a container, then 100 ml of dichloromethane is added, 5mg of 5-FU and 15mg of paclitaxel are added after the mixture is dissolved and mixed evenly, and the microspheres for injection containing 5 percent of 5-FU and 15 percent of paclitaxel are prepared by a spray drying method after the mixture is shaken again evenly. Then suspending the microspheres in physiological saline containing 1.5 percent of sodium carboxymethylcellulose to prepare the corresponding suspension type sustained-release injection with the viscosity of 380-460 cp (at the temperature of 25-30 ℃). The slow release injection has the release time in vitro physiological saline of 14-20 days and the release time under the skin of a mouse of about 25-35 days.
Example 3
The steps of the method for processing the sustained-release injection are the same as the example 2, but the difference is that the anticancer active ingredients and the weight percentage thereof are as follows: 15 percent of 5-FU and 5 percent of paclitaxel, and the viscosity of the suspension type sustained-release injection is 420cp-520cp (at 25 ℃ and 30 ℃). The slow release injection has the release time in vitro physiological saline of 15-22 days and the release time under the skin of a mouse of about 25-35 days.
Example 4.
80mg of PLGA (50: 50) copolymer with the molecular weight peak of 25000-50000 is respectively put into a container, then 100 ml of dichloromethane is added, 10mg of 5-FU and 10mg of paclitaxel are added after the mixture is dissolved and mixed evenly, and the microspheres for injection containing 10% of 5-FU and 10% of paclitaxel are prepared by a spray drying method after the mixture is shaken again evenly. Then suspending the microspheres in physiological saline containing 1.5 percent of sodium carboxymethylcellulose to prepare the corresponding suspension type sustained-release injection with the viscosity of 340-420 cp (at 25-30 ℃). The slow release injection has the release time of 14-20 days in-vitro physiological saline and the release time of about 20-25 days under the skin of a mouse.
Example 5.
70mg of PLGA (75: 25) with the molecular weight peak of 40000-60000 is respectively put into a container, then 100 ml of dichloromethane is added, 10mg of 5-FU and 20mg of paclitaxel are added after the mixture is dissolved and mixed evenly, and the microspheres for injection containing 10% of 5-FU and 20% of paclitaxel are prepared by a spray drying method after the mixture is shaken again evenly. Suspending the dried microspheres in physiological saline containing 1.5 percent of sodium carboxymethylcellulose to prepare the corresponding suspension type sustained-release injection. The slow release injection has the release time of 10-15 days in-vitro physiological saline and the release time of about 20-30 days under the skin of a mouse.
Example 6
80mg of PLGA (50: 50) with the molecular weight peak of 20000-40000 is respectively put into a container, then 100 ml of dichloromethane is added, after being dissolved and mixed evenly, 15mg of 5-FU and 5mg of oxypetaxel are added, after shaking up again, the microspheres for injection containing 15% of 5-FU and 5% of oxypetaxel are prepared by a spray drying method. Suspending the dried microspheres in physiological saline containing 1.5 percent of sodium carboxymethylcellulose to prepare the corresponding suspension type sustained-release injection. The slow release injection has the release time of 14-20 days in-vitro physiological saline and the release time of about 20-25 days under the skin of a mouse.
Example 7
The steps of the method for processing the sustained-release injection are the same as the example 6, but the difference is that the anticancer active ingredients and the weight percentage thereof are as follows: 5-30% of 5-FU in combination with 5-30% of paclitaxel, camptothecin or vinorelbine.
Example 8.
70mg of ethylene vinyl acetate copolymer (EVAc) is put into a container, 100 ml of dichloromethane is added to dissolve and mix evenly, 20mg of 5-FU and 10mg of camptothecin are added, the mixture is shaken up again, and then the spray drying method is used to prepare the microspheres for injection containing 20% of 5-FU and 10% of camptothecin. Then suspending the microspheres in injection containing 5-15% of sorbitol to prepare the corresponding suspension type sustained-release injection. The slow release injection has the release time of 10-15 days in-vitro physiological saline and the release time of about 20-30 days under the skin of a mouse.
Example 9.
The procedure of the process for preparing the sustained-release injection is the same as that of example 8, except that the anticancer active ingredients are: 10-20% of 5-FU and 10-20% of taxol, camptothecin and vinorelbine.
Example 10.
70mg of polifeprosan (p-carboxyphenylpropane (p-CPP): Sebacic Acid (SA) 50: 50) copolymer is put into a container, 100 ml of dichloromethane is added, after being dissolved and mixed evenly, 10mg of 5-FU and 20mg of camptothecin are added, after shaking up again, the microspheres for injection containing 10% of 5-FU and 20% of camptothecin are prepared by a spray drying method. Then suspending the microspheres in physiological saline containing 1.5 percent of sodium carboxymethylcellulose and 0.5 percent of Tween 80 to prepare the corresponding suspension type sustained-release injection. The slow release injection has the release time of 10-15 days in-vitro physiological saline and the release time of about 20-30 days under the skin of a mouse.
Example 11.
The procedure of the process for preparing the sustained-release injection is the same as that of example 10, except that the anticancer active ingredients are: a combination of 10% 5-FU with 20% paclitaxel, camptothecin or vinorelbine.
Example 12.
70mg of polifeprosan (p-carboxyphenylpropane (p-CPP): Sebacic Acid (SA) is 20: 80) copolymer is put into a container, 100 ml of dichloromethane is added, after being dissolved and mixed evenly, 15mg of 5-FU and 15mg of paclitaxel are added, after shaking up again, the microspheres for injection containing 15% of 5-FU and 15% of paclitaxel are prepared by a spray drying method. Then suspending the microspheres in physiological saline containing 1.5 percent of sodium carboxymethylcellulose, 15 percent of sorbitol and 0.2 percent of Tween 80 to prepare the corresponding suspension type sustained-release injection. The slow release injection has the release time of 10-15 days in-vitro physiological saline and the release time of about 20-30 days under the skin of a mouse.
Example 13.
The procedure of the process for preparing the sustained-release injection is the same as that of example 12, except that the anticancer active ingredients are: a combination of 15% 5-FU with 15% paclitaxel, camptothecin or vinorelbine.
Example 14
80mg of polifeprosan (p-carboxyphenylpropane (p-CPP): Sebacic Acid (SA) is 20: 80) copolymer is put into a container, 100 ml of dichloromethane is added, after being dissolved and mixed evenly, 7.5mg of vinorelbine and 12.5mg of 5-FU are added, after being shaken again evenly, the injection microsphere containing 7.5 percent of vinorelbine and 12.5 percent of 5-FU is prepared by a spray drying method. Then the microspheres are prepared into the corresponding sustained-release implant by a tabletting method. The slow release implant has the release time of 10-15 days in-vitro physiological saline and the release time of about 30-40 days under the skin of a mouse.
Example 15
The procedure of processing into a sustained-release implant was the same as in example 14, except that the anticancer active ingredient contained therein was: 12.5% of 5-FU in combination with 7.5% of paclitaxel, camptothecin or vinorelbine.
Example 16
70mg of PLGA (50: 50) with the molecular weight peak of 20000-40000 is put into a container, 100 ml of dichloromethane is added, after being dissolved and mixed evenly, 10mg of 5-FU and 20mg of paclitaxel are added, after being shaken again, the microspheres for injection containing 10% of 5-FU and 20% of paclitaxel are prepared by a spray drying method. Then the microspheres are prepared into the corresponding sustained-release implant by a tabletting method. The slow release implant has the release time of 15-25 days in vitro physiological saline and the release time of about 35-50 days under the skin of a mouse.
Example 17
70mg of PLA with the molecular weight peak of 20000-40000 is put into a container, 100 ml of dichloromethane is added, 10mg of 5-FU and 20mg of vinorelbine are added after the mixture is dissolved and mixed evenly, and the mixture is shaken up again and then spray-dried to prepare microspheres for injection containing 10% of 5-FU and 20% of vinorelbine. Then the microspheres are prepared into the corresponding sustained-release implant by a tabletting method. The sustained-release implant has the drug release time of 20-25 days in-vitro physiological saline and the drug release time of about 30-40 days under the skin of a mouse.
Example 18
70mg of PLGA (50: 50) with the molecular weight peak of 40000-60000 is put into a container, 100 ml of dichloromethane is added, after the mixture is dissolved and mixed evenly, 20mg of 5-FU and 10mg of vinorelbine are added, and after the mixture is shaken again, the microspheres for injection containing 20% of 5-FU and 10% of vinorelbine are prepared by a spray drying method. Then the microspheres are prepared into the corresponding sustained-release implant by a tabletting method. The sustained-release implant has the drug release time of 20-25 days in-vitro physiological saline and the drug release time of about 35-40 days under the skin of a mouse.
Example 19
The procedure for manufacturing the sustained-release implant was the same as in examples 17 and 18, except that the anticancer active ingredient contained:
(1) a combination of 15% 5-FU with 5% paclitaxel, camptothecin or vinorelbine; or
(2) A combination of 10% 5-FU with 10% paclitaxel, camptothecin or vinorelbine; or
(3) A combination of 5% 5-FU with 15% paclitaxel, camptothecin or vinorelbine.
Example 20
70mg of PLGA (50: 50) with a molecular weight peak of 25000-40000 is put into a container, 100 ml of dichloromethane is added, after being dissolved and mixed evenly, 20mg of 5-FU and 10mg of camptothecin are added, after being shaken again, the microspheres for injection containing 20% of 5-FU and 10% of camptothecin are prepared by a spray drying method. Then the microspheres are prepared into the corresponding sustained-release implant by a tabletting method. The sustained-release implant has the drug release time of 20-25 days in-vitro physiological saline and the drug release time of about 35-40 days under the skin of a mouse.
Example 21
70mg of PLA with the molecular weight peak of 25000-40000 is put into a container, 100 ml of dichloromethane is added, after the mixture is dissolved and mixed evenly, 10mg of 5-FU and 20mg of camptothecin are added, the mixture is shaken up again and then the spray drying method is used for preparing the microspheres for injection containing 10% of 5-FU and 20% of camptothecin. Then the microspheres are prepared into the corresponding sustained-release implant by a tabletting method. The sustained-release implant has the drug release time of 20-25 days in-vitro physiological saline and the drug release time of about 30-35 days under the skin of a mouse.
Example 22
The procedure of the process for preparing the sustained release formulation is the same as in examples 1-21, except that the sustained release excipient used is one or a combination of the following:
a) polylactic acid (PLA) with a molecular weight peak of 10000-30000, 30000-60000, 60000-100000 or 100000-150000;
b) a copolymer (PLGA) of polyglycolic acid and glycolic acid with a molecular weight peak of 10000-30000, 30000-60000, 60000-100000 or 100000-150000, wherein the ratio of polyglycolic acid to glycolic acid is 50-95: 50-50;
c) ethylene vinyl acetate copolymer (EVAc);
d) p-carboxyphenylpropane (p-CPP) to Sebacic Acid (SA) copolymer (polifeprosan) 10: 90, 20: 80, 30: 70, 40: 60, 50: 50 or 60: 40;
e) FAD and Sebacic Acid (SA) copolymer;
f) xylitol, oligosaccharide, chondroitin, chitin, hyaluronic acid, collagen, gelatin or albumin glue.
Example 23.
The procedure for preparing a sustained release injection is the same as in examples 1 to 21, except that the suspending agent used is one or a combination of the following:
a) 0.5-3.0% carboxymethylcellulose (sodium);
b) 5-15% mannitol;
c) 5-15% sorbitol;
d) 0.1-1.5% of surface active substances;
e) 0.1-0.5% tween 20.
The above examples are intended to illustrate, but not limit, the application of the invention.
The invention is disclosed and claimed.
Claims (10)
1. A sustained-release injection carrying fluorouracil and a synergist thereof comprises the following components:
(A) a sustained release microsphere comprising:
0.5-60% of anticancer active ingredient
Sustained release auxiliary materials 40-99%
0.0 to 30 percent of suspending agent
The above are weight percentages
And
(B) the solvent is common solvent or special solvent containing suspending agent.
Wherein,
the anticancer active ingredients are 5-FU and 5-FU synergist;
the suspending agent is selected from one or more of sodium carboxymethylcellulose, iodine glycerol, dimethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, Tween 20, Tween 40 and Tween 80,
the viscosity of the injection is 50-1000 cp (at 20-30 deg C)
2. The sustained-release anticancer injection according to claim 1, wherein the synergist is selected from one of paclitaxel, camptothecin, vinorelbine or their combination.
3. The sustained-release anticancer injection according to claim 1, wherein the sustained-release anticancer injection comprises the following anticancer active ingredients: 5-30% of 5-FU in combination with 5-30% of paclitaxel, camptothecin or vinorelbine.
The above are all weight percentages.
4. The sustained-release anticancer injection according to claim 1, wherein the sustained-release anticancer injection comprises the following anticancer active ingredients:
(1) a combination of 15% 5-FU with 5% paclitaxel, camptothecin or vinorelbine; or
(2) A combination of 10% 5-FU with 10% paclitaxel, camptothecin or vinorelbine; or
(3) A combination of 5% 5-FU with 15% paclitaxel, camptothecin or vinorelbine; or
(4) A combination of 25% 5-FU with 5% paclitaxel, camptothecin or vinorelbine.
5. The sustained-release anticancer injection according to claim 1, wherein the sustained-release excipient is selected from one or a combination of the following:
a) polylactic acid;
b) copolymers of polyglycolic acid and glycolic acid;
c) polifeprosan;
d) ethylene vinyl acetate copolymers;
e) FAD and sebacic acid copolymer.
6. The sustained-release anticancer injection according to claim 1, wherein the suspending agent is one or a combination of the following:
a) 0.5-3.0% carboxymethylcellulose (sodium);
b) 5-15% mannitol;
c) 5-15% sorbitol;
d) 0.1-1.5% of surface active substances;
e) 0.1-0.5% tween 20, or
f) (iodine) glycerol, dimethicone, propylene glycol or carbomer.
7. The sustained-release anticancer injection according to claim 1, wherein the suspending agent is one of the following:
A) 0.5-5% of sodium carboxymethylcellulose and 0.1-0.5% of Tween 80;
B) 5-20% of mannitol and 0.1-0.5% of Tween 80; or
C)0.5 to 5 percent of sodium carboxymethylcellulose, 5 to 20 percent of sorbitol and 0.1 to 0.5 percent of Tween 80.
8. The sustained-release anticancer microspheres according to claim 1, which are used for preparing sustained-release implants for treating extracranial solid tumors or brain tumors originated from human and animals.
9. The sustained-release anticancer implant according to claim 8, characterized in that: the anticancer active ingredients are:
(1) a combination of 15% 5-FU with 5% paclitaxel, camptothecin or vinorelbine; or
(2) A combination of 10% 5-FU with 10% paclitaxel, camptothecin or vinorelbine; or
(3) A combination of 5% 5-FU with 15% paclitaxel, camptothecin or vinorelbine; or
(4) A combination of 25% 5-FU with 5% paclitaxel, camptothecin or vinorelbine.
The slow release auxiliary material is selected from one or the combination of the following materials:
a) polylactic acid;
b) copolymers of polyglycolic acid and glycolic acid;
c) polifeprosan;
d) ethylene vinyl acetate copolymers;
e) FAD and sebacic acid copolymer.
10. The sustained-release anticancer implant according to claim 8, wherein the extracranial solid tumor is primary or secondary cancer, sarcoma or carcinosarcoma originated from human or animal kidney, liver, gallbladder, head and neck, oral cavity, thyroid gland, skin, mucosa, gland, blood vessel, bone tissue, lymph node, lung, esophagus, stomach, breast, pancreas, eye, nasopharynx, uterus, ovary, endometrium, cervix, prostate, bladder, colon or rectum.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2006102009415A CN1969823A (en) | 2006-09-28 | 2006-09-28 | Sustained release agent containing fluorouracil and synergist thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2006102009415A CN1969823A (en) | 2006-09-28 | 2006-09-28 | Sustained release agent containing fluorouracil and synergist thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1969823A true CN1969823A (en) | 2007-05-30 |
Family
ID=38110972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006102009415A Pending CN1969823A (en) | 2006-09-28 | 2006-09-28 | Sustained release agent containing fluorouracil and synergist thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1969823A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1957920B (en) * | 2006-09-28 | 2010-05-19 | 山东蓝金生物工程有限公司 | Anti cancer slow release agent carrying fluorouracil and synergist |
CN101972493A (en) * | 2010-10-15 | 2011-02-16 | 中国人民解放军第二军医大学 | Visualized iodized oil-5-fluorouracil loaded polylactic acid microsphere preparation and preparation method thereof |
-
2006
- 2006-09-28 CN CNA2006102009415A patent/CN1969823A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1957920B (en) * | 2006-09-28 | 2010-05-19 | 山东蓝金生物工程有限公司 | Anti cancer slow release agent carrying fluorouracil and synergist |
CN101972493A (en) * | 2010-10-15 | 2011-02-16 | 中国人民解放军第二军医大学 | Visualized iodized oil-5-fluorouracil loaded polylactic acid microsphere preparation and preparation method thereof |
CN101972493B (en) * | 2010-10-15 | 2013-03-13 | 中国人民解放军第二军医大学 | Visualized iodized oil-5-fluorouracil loaded polylactic acid microsphere preparation and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1969818A (en) | Anticancer sustained release injection containing epothilone derivatives | |
CN101433520A (en) | Anticancer sustained-release agent containing epothilone | |
CN101396340A (en) | Anti-cancer sustained-released injection containing epothilone derivate | |
CN101396342A (en) | Anti-cancer sustained-released injection containing epothilone derivate | |
CN1969816A (en) | Anticancer sustained release agent containing epothilone | |
CN101380303A (en) | Anti-cancer medicine sustained-released injection loaded with platinum compound and synergist thereof | |
CN1969825A (en) | Sustained release agent containing fluorouracil and synergist thereof | |
CN1969820A (en) | Anticancer pharmaceutical composition | |
CN1969823A (en) | Sustained release agent containing fluorouracil and synergist thereof | |
CN1969824A (en) | Anticancer sustained release agent containing fluorouracil and synergist thereof | |
CN100500215C (en) | Slow-released injection containing methotrexate and its synergist | |
CN1969826A (en) | Fluorouracil and its synergist carried sustained release agent | |
CN100998558A (en) | Slow-release anticarcinogen contg. carmustine and fluorouracil | |
CN100531715C (en) | Slow-released methotrexate injection | |
CN101254166A (en) | An anticancer sustained release injection carrying clorfarabine and its synergist | |
CN100531718C (en) | Slow-released injection containing methotrexate synergist | |
CN101361710A (en) | Anticancer composition containing tuomatinib | |
CN100531719C (en) | Slow-released injection containing methotrexate synergist | |
CN1961863A (en) | An anticancer sustained releasing agent containing mesenchyme hydrolytic reagent and cytotoxic drug | |
CN101002729A (en) | Slow released anticarcinogen containing vasoinhibitor | |
CN101011343A (en) | Slow release injection containing anti-metabolism medicament and alkylating agent | |
CN101427996A (en) | Novel anticancer sustained-release injection | |
CN101637446A (en) | Injection containing compound anti-cancer slow release agent | |
CN101637445A (en) | Compound anti-cancer slow release agent | |
CN101427995A (en) | Anticancer sustained-release agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |